



Ferroptosis Pathways in Neurodegenerative and Neuropsychiatric Diseases

Guest Editor:

Dr. Jack T. Rogers

Neurochemistry Laboratory,
Department of Psychiatry-
Neuroscience, Massachusetts
General Hospital and Harvard
Medical School, 149 13th Street,
Charlestown, Boston, MA 02129,
USA

Deadline for manuscript
submissions:

15 August 2024

Message from the Guest Editor

Ferroptosis is a newly discovered pathway towards programmed cell death. It is caused by an excess of free intracellular iron that leads to cytotoxic lipid (hydro-) peroxidation. Erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants, including those generated by iron-associated radicals. A growing body of evidence suggests that perturbations of iron homeostasis play a key role in the occurrence and development of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and vascular dementia, which suggests that ferroptosis may be involved in regulating the progression of not only neurodegenerative but also neuropsychiatric diseases.

The Special Issue welcomes reviews, as well as original *in vivo*, *in vitro*, and preclinical research focused on the regulatory mechanism of ferroptosis and its various effects in neurodegenerative diseases, in order to provide a reference for the research on ferroptosis in neurodegenerative and neuropsychiatric diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)